↓ Skip to main content

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Overview of attention for article published in Lancet Oncology, October 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
6 news outlets
policy
1 policy source
twitter
944 X users
patent
22 patents

Citations

dimensions_citation
837 Dimensions

Readers on

mendeley
414 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Published in
Lancet Oncology, October 2009
DOI 10.1016/s1470-2045(09)70284-0
Pubmed ID
Authors

S Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, Rafael Fonseca, David H Vesole, Michael E Williams, Rafat Abonour, David S Siegel, Michael Katz, Philip R Greipp, for the Eastern Cooperative Oncology Group

X Demographics

X Demographics

The data shown below were collected from the profiles of 944 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 414 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
France 1 <1%
Italy 1 <1%
Brazil 1 <1%
Spain 1 <1%
Japan 1 <1%
United States 1 <1%
Unknown 406 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 67 16%
Other 60 14%
Student > Ph. D. Student 47 11%
Student > Bachelor 38 9%
Student > Master 35 8%
Other 88 21%
Unknown 79 19%
Readers by discipline Count As %
Medicine and Dentistry 213 51%
Agricultural and Biological Sciences 28 7%
Pharmacology, Toxicology and Pharmaceutical Science 22 5%
Biochemistry, Genetics and Molecular Biology 18 4%
Nursing and Health Professions 10 2%
Other 33 8%
Unknown 90 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 423. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 March 2024.
All research outputs
#68,863
of 25,564,614 outputs
Outputs from Lancet Oncology
#82
of 6,908 outputs
Outputs of similar age
#100
of 107,984 outputs
Outputs of similar age from Lancet Oncology
#2
of 28 outputs
Altmetric has tracked 25,564,614 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,908 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 107,984 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.